Cargando…
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336046/ https://www.ncbi.nlm.nih.gov/pubmed/35902886 http://dx.doi.org/10.1186/s13148-022-01316-5 |
_version_ | 1784759460760125440 |
---|---|
author | Hogg, Simon J. Motorna, Olga Kearney, Conor J. Derrick, Emily B. House, Imran G. Todorovski, Izabela Kelly, Madison J. Zethoven, Magnus Bromberg, Kenneth D. Lai, Albert Beavis, Paul A. Shortt, Jake Johnstone, Ricky W. Vervoort, Stephin J. |
author_facet | Hogg, Simon J. Motorna, Olga Kearney, Conor J. Derrick, Emily B. House, Imran G. Todorovski, Izabela Kelly, Madison J. Zethoven, Magnus Bromberg, Kenneth D. Lai, Albert Beavis, Paul A. Shortt, Jake Johnstone, Ricky W. Vervoort, Stephin J. |
author_sort | Hogg, Simon J. |
collection | PubMed |
description | BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated transcriptomic and epigenomic profiling to characterize the acute epigenetic changes induced by IFNγ stimulation in a murine breast cancer model. RESULTS: We identified de novo activation of cis-regulatory elements bound by Irf1 that were characterized by increased chromatin accessibility, differential usage of pro-inflammatory enhancers, and downstream recruitment of BET proteins and RNA polymerase II. To functionally validate this hierarchical model of IFNγ-driven transcription, we applied selective antagonists of histone acetyltransferases P300/CBP or acetyl-lysine readers of the BET family. This highlighted that histone acetylation is an antecedent event in IFNγ-driven transcription, whereby targeting of P300/CBP acetyltransferase activity but not BET inhibition could curtail the epigenetic remodeling induced by IFNγ through suppression of Irf1 transactivation. CONCLUSIONS: These data highlight the ability for epigenetic therapies to reprogram pro-inflammatory gene expression, which may have therapeutic implications for anti-tumor immunity and inflammatory diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01316-5. |
format | Online Article Text |
id | pubmed-9336046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93360462022-07-30 Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer Hogg, Simon J. Motorna, Olga Kearney, Conor J. Derrick, Emily B. House, Imran G. Todorovski, Izabela Kelly, Madison J. Zethoven, Magnus Bromberg, Kenneth D. Lai, Albert Beavis, Paul A. Shortt, Jake Johnstone, Ricky W. Vervoort, Stephin J. Clin Epigenetics Research BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated transcriptomic and epigenomic profiling to characterize the acute epigenetic changes induced by IFNγ stimulation in a murine breast cancer model. RESULTS: We identified de novo activation of cis-regulatory elements bound by Irf1 that were characterized by increased chromatin accessibility, differential usage of pro-inflammatory enhancers, and downstream recruitment of BET proteins and RNA polymerase II. To functionally validate this hierarchical model of IFNγ-driven transcription, we applied selective antagonists of histone acetyltransferases P300/CBP or acetyl-lysine readers of the BET family. This highlighted that histone acetylation is an antecedent event in IFNγ-driven transcription, whereby targeting of P300/CBP acetyltransferase activity but not BET inhibition could curtail the epigenetic remodeling induced by IFNγ through suppression of Irf1 transactivation. CONCLUSIONS: These data highlight the ability for epigenetic therapies to reprogram pro-inflammatory gene expression, which may have therapeutic implications for anti-tumor immunity and inflammatory diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01316-5. BioMed Central 2022-07-28 /pmc/articles/PMC9336046/ /pubmed/35902886 http://dx.doi.org/10.1186/s13148-022-01316-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hogg, Simon J. Motorna, Olga Kearney, Conor J. Derrick, Emily B. House, Imran G. Todorovski, Izabela Kelly, Madison J. Zethoven, Magnus Bromberg, Kenneth D. Lai, Albert Beavis, Paul A. Shortt, Jake Johnstone, Ricky W. Vervoort, Stephin J. Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title | Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title_full | Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title_fullStr | Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title_full_unstemmed | Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title_short | Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer |
title_sort | distinct modulation of ifnγ-induced transcription by bet bromodomain and catalytic p300/cbp inhibition in breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336046/ https://www.ncbi.nlm.nih.gov/pubmed/35902886 http://dx.doi.org/10.1186/s13148-022-01316-5 |
work_keys_str_mv | AT hoggsimonj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT motornaolga distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT kearneyconorj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT derrickemilyb distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT houseimrang distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT todorovskiizabela distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT kellymadisonj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT zethovenmagnus distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT brombergkennethd distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT laialbert distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT beavispaula distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT shorttjake distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT johnstonerickyw distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer AT vervoortstephinj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer |